SCHEMBL4952983

SCHEMBL4952983

CSCC(NC(C)=O)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.59
KDM4E B2RXH2 1/20 0.59
THRB P10828 1/20 0.59
ALOX15 P16050 1/20 0.59
NFKB1 P19838 1/20 0.59
PTGS2 P35354 1/20 0.59
THPO P40225 1/20 0.59
RECQL P46063 1/20 0.59
BLM P54132 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
ALDH1A1 P00352 3/20 0.57
FOLH1 Q04609 5/20 0.43
NAALAD2 Q9Y3Q0 3/20 0.43
RIMKLA Q8IXN7 1/20 0.43
PRNP P04156 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
LMNA P02545 2/20 0.40
GNPAT O15228 1/20 0.40
PAM P19021 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921443 1.00 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL6658481 1.00 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL25329304 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL16745722 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL2140974 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL24067699 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL308082 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL31405642 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL6308419 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL308083 0.86 MAPT (0.59) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110946772-A Toothpaste for preventing dental diseases and preparation method thereof 苏格格 2020-04-03 CN claimed
US-20030162732-A1 Combination of aminosugars and cysteine or cysteine derivatives ASTION DEVELOPMENT A/S (DK) 2003-08-28 US claimed
US-20030158118-A1 Combination of cimetidine and cysteine derivatives for treating cancer WEIDNER MORTEN SLOTH (DK) 2003-08-21 US claimed
WO-2003045359-A2 COMBINATION OF CIMETIDINE AND CYSTEINE DERIVATIVES FOR TREATING CANCER ASTION ONCOLOGY APS (DK) 2003-06-05 WO claimed
WO-2003002125-A2 COMBINATION OF AMINOSUGARS AND CYSTEINE OR CYSTEINE DERIVATIVES ASTION A/S (DK) 2003-01-09 WO claimed
US-20260102334-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS NEURODERM LTD (IL) 2026-04-16 US disclosed
US-20250073193-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS NEURODERM LTD (IL) 2025-03-06 US disclosed
CN-113274579-B Device for subcutaneous delivery of fluid drugs 纽罗德姆有限公司 2024-02-13 CN disclosed
EP-4299128-A2 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS Neuroderm Ltd. (IL) 2024-01-03 EP disclosed
US-20230240980-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS NEURODERM LTD (IL) 2023-08-03 US disclosed
US-20230096364-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS NEURODERM LTD (IL) 2023-03-30 US disclosed
CN-113274578-B Device for subcutaneous delivery of fluid drugs 纽罗德姆有限公司 2022-06-03 CN disclosed
EP-0373339-A1 Silver halide recording material Agfa-Gevaert AG (DE) 1990-06-20 EP disclosed
US-4482495-A CHEMICAL INTERMEDIATES FOR ANALGESICS STERLING DRUG INC. (US) 1984-11-13 US disclosed
EP-0051682-B1 CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1984-09-05 EP disclosed
US-4440788-A REGENERATION OF LIVER CELLS MITSUBISHI CHEMICAL INDUSTRIES, LIMITED (JP) 1984-04-03 US disclosed
US-4405800-A ANALGESICS STERLING DRUG INC. (US) 1983-09-20 US disclosed
US-4361703-A ANALGESICS STERLING DRUG INC. (US) 1982-11-30 US disclosed
EP-0051682-A1 CYSTEINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1982-05-19 EP disclosed
US-4181719-A Analgesic N-acetyl-para-aminophenyl N'-acetylaminothioalkanoates STERLING DRUG INC. (US) 1980-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162732-A1 Combination of aminosugars and cysteine or cysteine derivatives CBS, CTH, AADAT MAPT 2801/4885KDM4E 3811/4885THRB 4391/4885
US-20230096364-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS DDT, DDC, COMT MAPT 888/4885KDM4E 1869/4885THRB 1305/4885
US-20030158118-A1 Combination of cimetidine and cysteine derivatives for treating cancer MGMT, CMA1, CYSLTR2 MAPT 4793/4885KDM4E 2224/4885THRB 4256/4885
US-20260102334-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS COMT, PARK7, DDT MAPT 792/4885KDM4E 656/4885THRB 3145/4885
US-20250073193-A1 DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS DDT, DDC, COMT MAPT 888/4885KDM4E 1869/4885THRB 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.